DDInter85 DDInter1763
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Amphotericin B {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Amphotericin B {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Amphotericin B {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Amphotericin B {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Amphotericin B {u} (Compound) resembles {v} (Compound) Natamycin
Natamycin {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Amphotericin B {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Amphotericin B {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Amphotericin B {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Temsirolimus
Amphotericin B {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) downregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Amphotericin B {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Voriconazole {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Temsirolimus
Amphotericin B may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Amphotericin B (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Amphotericin B (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Temsirolimus (Compound)
Amphotericin B (Compound) resembles Natamycin (Compound) and Natamycin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Temsirolimus (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Temsirolimus (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) downregulates LRPAP1 (Gene) and LRPAP1 (Gene) is downregulated by Temsirolimus (Compound)
Amphotericin B may cause a minor interaction that can limit clinical effects when taken with Voriconazole and Voriconazole (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Temsirolimus (Compound)